Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ZVRA
#2506
Zevra Therapeutics, Inc. Common Stock
8.930
0
+0.68%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+0.68%
Monthly Change
0.00%
6 month change
-16.07%
Year Change
-16.07%
Previous Close
8.870
0
Open
8.930
0
Bid
Ask
Low
8.930
0
High
8.930
0
Volume
101
Markets
US Stock Market
Healthcare
ZVRA
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Dividends per share
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
News
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates
Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates
Neil F. McFarlane, Zevra Therapeutics president, sells $125k in shares
Zevra Therapeutics CMO Quartel sells $40k in shares
Schafer Joshua, CCO of Zevra, sells $29,800 in ZVRA stock
Zevra Therapeutics CEO McFarlane sells $853k in shares
Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Zevra Stock: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market (ZVRA)
Zevra Therapeutics stock maintains Buy rating at H.C. Wainwright on expanded access deal
Zebra Pharmaceuticals at Guggenheim Conference: Strategic Growth in Rare Diseases
Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More - Palantir Technologies (NASDAQ:PLTR)